This interactive workshop addresses a critical question in clinical research:
how can monitoring strategies designed to accelerate timelines impact overall study quality,
oversight, and audit readiness—and how can teams effectively respond?
Using a real-world case study from a large, multi-site investigational device trial enrolling over 35,000 participants, this workshop will guide participants through the evolution of monitoring strategies implemented to resolve source data verification (SDV) backlog and meet interim analysis
timelines. Participants will explore how intensive approaches—including rapid scaling of monitoring
resources, hybrid monitoring models, and SDV-only monitoring visits—can introduce unintended
risks to monitoring effectiveness, data integrity, and regulatory compliance.
Through a combination of facilitated discussion and hands-on group exercises, participants will actively engage in identifying operational and regulatory risks across multiple levels of study execution, including CRA performance, site engagement, data management, and oversight processes. Participants will work collaboratively to perform root cause analysis and develop
corrective and preventive action (CAPA) strategies based on realistic study scenarios.
The workshop will introduce a structured monitoring effectiveness framework that integrates risk-based monitoring principles, communication pathways, and sustainable resourcing strategies.
Participants will apply this framework to both the case study and their own clinical trial environments, enabling direct translation of workshop content into practice.
As the lead presenter and Clinical Lead on this study, I will facilitate discussion, guide interactive exercises, and provide practical insights into monitoring strategy development, risk identification, and implementation of mitigation approaches. Emphasis will be placed on balancing operational
efficiency with comprehensive oversight to ensure data integrity and audit readiness.
Participants will leave with practical tools, including a monitoring effectiveness framework, risk identification checklist, and CAPA development approach, which can be immediately applied to
improve monitoring effectiveness and study execution in complex clinical trials.